Retatrutide is studied as a triple agonist, engaging three receptors — GIP, GLP-1, and glucagon. It is the most receptor-diverse compound in the incretin research class.
Three pathways at once
Adding glucagon-receptor activity to the two incretin receptors gives researchers a model for how multiple metabolic pathways interact when engaged simultaneously. See the incretin receptors explained and how it sits within the class.
Product page: Retatrutide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.